Compare Amylx Pharmaceuticals Inc (AMLX) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs General Mills, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.91 (market cap $2.64B), while General Mills, Inc. trades at $38.04 (market cap $20.24B). The key difference: General Mills, Inc. is far larger — about 7.7× Amylx Pharmaceuticals Inc's market cap, and General Mills, Inc. pays a 6.43% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | GIS | |
|---|---|---|
Market Cap | $2.64B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $51.11 |
52-Week Low | $7.82 | $32.17 |
Enterprise Value | $2.39B | $33.73B |
Dividend Yield | — | 6.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
General Mills (GIS) trades at $37.26, up 1.0% with a bullish technical signal. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), but maintains strong cash flow from operations ($2.92B). Recent earnings beat expectations in Q3 2025 and Q2 2026, while analyst sentiment remains cautious with 61% hold ratings. The company continues dividend payments and focuses on cost-saving initiatives.
Investment outlook remains balanced with attractive valuation (P/E 9.23) offset by margin pressures. Key opportunities include dividend yield and cost savings program, while risks involve declining profitability and competitive pressures. Wall Street consensus price target of $35.36 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
